AzTrials
AzTrials

Women Undergoing Oocyte Retrieval ProceduresNCT04933058

Opioid Based Analgesia vs Non-opioid Analgesia for Oocyte Retrieval Procedure

A study testing IV acetaminophen and IV fentanyl in people with Women Undergoing Oocyte Retrieval Procedures, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

It is unclear whether routine addition of opioids for analgesia during minor gynecological procedures is beneficial. In this single-center randomized single-blinded trial, the investigators aim to test the primary hypothesis that opioid-sparing anesthesia regimen including intravenous acetaminophen is non-inferior to… Read more about this study

Who is it for?
Ages 18 to 45 years, women only
What is being tested?
IV acetaminophen and IV fentanyl
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteIsrael
Study dates
5 Dec 2021to 30 Oct 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Written informed consent
  • 18-45 years old
  • American Society of Anesthesiologists (ASA) physical status 1-2
  • Undergoing oocyte retrieval procedures
  • Planned number of oocytes to be retrieved <15

Who cannot join

  • Known allergy to fentanyl, acetaminophen, dipyrone, lidocaine, propofol or NSAIDs.
  • Endometriosis
  • Diagnosis of chronic pain
  • Opioid dependency, defined by consumption of oral morphine equivalent of greater than or equal to 60mg a day for 7 days or longer, for any time period.
  • Weight < 50 kg
  • Cannabis use
Show all 10Show fewer
  • Major psychiatric disorder - Schizophrenia, bipolar disorder, major depression.
  • Epilepsy disorder under anti-convulsant therapy.
  • Renal insufficiency, defined as creatinine clearance <60 ml/hr
  • Hepatic disease

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • tel aviv SMO

    Tel Aviv

Other trials in Israel

About this study

Official title: Opioid Based Analgesia vs Non-opioid Analgesia for Oocyte Retrieval Procedure - a Randomized Clinical Trial

It is unclear whether routine addition of opioids for analgesia during minor gynecological procedures is beneficial. In this single-center randomized single-blinded trial, the investigators aim to test the primary hypothesis that opioid-sparing anesthesia regimen including intravenous acetaminophen is non-inferior to a similar anesthesia regimen containing fentanyl in providing postoperative analgesia in women recovering from oocyte retrieval procedures for in vitro fertilization. The investigators also aim to assess the difference in incidence of patient-reported opioid related adverse-effects between the two groups, time to discharge from the post-anesthesia care unit and postoperative rescue analgesia requirements. If we demonstrate no clinically important difference between the two interventions, clinicians may be able to substantially reduce the amount of opioids administered to patients undergoing minor ambulatory procedures, and potentially decrease the associated opioid related adverse effects.

Read the detailed description

Study Overview The investigators propose a single-center randomized single-blinded clinical trial in which healthy women undergoing oocyte retrieval procedures under general anesthesia will be randomized to receive either 1.5mcg/kg fentanyl or IV acetaminophen as part of multimodal analgesia. The investigators will evaluate the effects of an opioid-free anesthesia on pain scores, analgesic medication consumption during the initial two postoperative hours, and time to discharge from PACU, compared to an opioid-containing anesthesia.The investigators will also compare the prevalence of opioid-related sedation side effect between opioid-free anesthesia and opioid-containing anesthesia.

Setting and Population Inclusion Criteria

  1. Written informed consent 2. 18-45 years old 3. American Society of Anesthesiologists (ASA) physical status 1-2 4. Undergoing oocyte retrieval procedures 5. Planned number of oocytes to be retrieved <15 Exclusion Criteria
  2. Known allergy to fentanyl, acetaminophen, dipyrone, lidocaine, propofol or NSAIDs.
  3. Endometriosis
  4. Diagnosis of chronic pain
  5. Opioid dependency, defined by consumption of oral morphine equivalent of greater than or equal to 60mg a day for 7 days or longer, for any time period.
  6. Weight < 50 kg
  7. Cannabis use
  8. Major psychiatric disorder - Schizophrenia, bipolar disorder, major depression.
  9. Epilepsy disorder under anti-convulsant therapy.
  10. Renal insufficiency, defined as creatinine clearance <60 ml/hr
  11. Hepatic disease

Withdrawal Criteria

  1. Patients are free to withdraw from the study at any time, for any reason.
  2. Patients may be withdrawn from the study by a member of the study team or the clinical team, if seems appropriate for patient's safety or well-being. Examples of such events include (but are not limited) to: an allergic reaction, analgesic failure per acute pain service judgement and significant patient discomfort.
  3. Reason for exclusion will be documented, and patients will be asked to continue follow-up according to the intention-to-treat principle

Protocol

The investigators propose a randomized, single-blinded single-center clinical trial. After confirming eligibility, patients will be approached before the procedure for possible enrollment in the study. After thorough explanation, written informed consent will be obtained. Patients will be randomized in a 1:1 ratio by a web-based software to receive either:

  1. Opioid-free anesthesia, including
  2. IV propofol 1-1.5 mg/kg
  3. IV acetaminophen 1000mg
  4. IV dipyrone 1000mg
  5. IV lidocaine 1mg/kg
  6. IV dexacort 4mg
  7. PR diclofenac 50 mg
  8. Opioid-supplemented anesthesia, including
  9. IV propofol 1-1.5 mg/kg
  10. IV fentanyl 1.5 mcg/kg
  11. IV dipyrone 1000mg
  12. IV lidocaine 1mg/kg
  13. IV dexacort 4mg
  14. PR diclofenac 50 mg

The anesthesiologist performing the procedure will not be blinded to group allocation, but other research team members and caregivers who evaluate the patients after the procedure will be.

General anesthesia will be induced according to the group allocation as mentioned above. Anesthesia maintenance will be achieved with 50% N2O via a face-mask, and additional doses of 10-20 mg of propofol as needed. Ketamine will not be allowed. Postoperatively, intravenous tramadol 100 mg will be ordered for breakthrough pain as well as intravenous ondansetron 4mg and metoclopramide 10mg for nausea and vomiting. Patients will be followed until home discharge. The rest of postoperative care will be conducted according to standard departmental procedures by nurses and physicians.

Measurements

  • Patient characteristics and demographic data including age, weight, body mass index (BMI), tobacco use, prior IVF treatment, history of pain after previous IVF, chronic pain, chronic medication use, and American Society of Anesthesiologists (ASA) physical status will be obtained from the medical record and patient interview.
  • Postoperative pain scores will be documented on an 11-point Numerical Rating Scale (NRS) from 0 (no pain) to 10 (worst pain imaginable) at least once every 30 minutes for the initial two postoperative hours.
  • Opioid-induced sedation will be captured through the Passero opioid-induced sedation scale (Appendix A) 20 minutes after patient admission to the recovery room.
  • Patient satisfaction with the anesthesia will be assessed using Likert scale from 1 to 5 grading "how satisfied are the participant with the pain management they received today?"
  • Time of discharge will be captured from the patient's electronic medical record and/or from patient interview.

Sample Size Considerations To test a unilateral non-inferiority hypothesis, assuming a 2.5% significance level, power of 80%, standard deviation of 2 points, a non-inferiority delta of no more than 1.5 points in the 11-point NRS pain scale between the two groups, and assumed pooled variance of 6, we will need a sample size of 42 patients in each group. Accounting for a predicted loss to follow-up of up to 20% of patients, we aim to recruit 100 patients.

Being tested
IV acetaminophen, IV fentanyl

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IV acetaminophenDrug

    Pain management

  • IV fentanylDrug

    Pain management

Study groups in NCT04933058
Study groupRoleWhat they receive
Opioid-free anesthesiaExperimental1. IV propofol 1-1.5 mg/kg 2. IV acetaminophen 1000mg 3. IV dipyrone 1000mg 4. IV lidocaine 1mg/kg 5. IV dexacort 4mg 6. PR diclofenac 50 mg
Receives: Drug: IV acetaminophen
Opioid-supplemented anesthesiaActive comparator1. IV propofol 1-1.5 mg/kg 2. IV fentanyl 1.5 mcg/kg 3. IV dipyrone 1000mg 4. IV lidocaine 1mg/kg 5. IV dexacort 4mg 6. PR diclofenac 50 mg
Receives: Drug: IV fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the difference in average pain scores

    We will test the difference in average pain scores between the groups in a non-inferiority model. All pain scores obtained during the initial two postoperative hours will be averaged and compared between the groups. The non-inferiority delta will be defined a priori as no worse than 1.5 points in average pain score. Overall alpha will be 0.05. NRS Scale from 0-10, zero is no pain.

    Measured: 1 year

  2. the dependent categorical variable of time-to-discharge readiness

    The secondary analysis will compare the dependent variable of time-to-discharge from postanesthesia care unit (PACU) readiness at 60 mins (yes/no) between the two study groups and will be reported as number (proportions). We will also record the time from arrival until discharge from PACU reported as the median [interquartile range] time in each group. Overall alpha will be 0.05.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jun 2021
  2. Study start5 Dec 2021
  3. Primary completion30 Oct 2022
  4. Study completion30 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04933058
Sponsor's protocol ID
1025-20-TLV
Status last verified
Mar 2023
First submitted
13 Jun 2021
Last updated
29 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Farladansky E, Cohen B, Almog B, Weiniger C, Hazan S, Barzilay L, Haim S. Intraoperative fentanyl versus paracetamol for ultrasound-guided oocyte retrieval analgesia: a randomised clinical trial. Int J Obstet Anesth. 2025 Aug;63:104681. doi: 10.1016/j.ijoa.2025.104681. Epub 2025 May 10.

    PubMed 40451048

Questions about this trial

What is this clinical trial studying?

A study testing IV acetaminophen and IV fentanyl in people with Women Undergoing Oocyte Retrieval Procedures, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the difference in average pain scores (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04933058, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in